GSK will invest $360.3 million at three of its manufacturing sites in the UK to boost production and support delivery of its latest innovative respiratory and large molecule biological medicines. According to the company, the vast majority of these products will be for export to global markets.
The funds will be used in sites at Barnard Castle, Co. Durham; Montrose, Scotland; and Ware, Hertfordshire.
GSK currently has nine sites in the UK, employing approximately 6,000 people. The company said it views the UK as an attractive location for investment in advanced manufacturing due to a number of factors including the skilled workforce, technological and scientific capabilities & infrastructure and a competitive corporate tax system.
Andrew Witty, CEO, GSK said, "Today’s announcement reflects further investment to support our pharmaceutical pipeline and meet growing demand for our innovative portfolio of newly launched products. It is testament to our skilled UK workforce and the country’s leading position in life sciences that we are making these investments in advanced manufacturing here. From their manufacture in the UK, many of these medicines will be sent to patients around the world."
Read the press release